The potential of the market access of a drug depends on the value story and the ability to document the value for money of a new drug. A good value story documents both unmet need, efficacy and comparative effectiveness in the real world. The documentation must follow the mode of action of the drug as well as the main bother of the patients. Market access evidence can be developed from a multitude of sources such as registry studies documenting the risk of no treatment, real life studies documenting undesirable behaviour at the physician, e.g. patient meetings or discrete choice studies, revealing the true unmet need from the patient perspective.
Example of a Market access problem solved by Pharma Evidence
Our client wanted to understand the market access strategies of their main competitor and develop a market access strategy based on gaps.
Pharma Evidence went through literature and economic models to re-construct the market access strategy of the competitor, pin pointed the gaps in the strategy and described the market access way forward based partly on the evidence already produced by the competitor and partly on new surveys to support the specific mode of action of the new drug.